Biomarin Pharmaceutical (BMRN) Work In Process (2010 - 2021)

Biomarin Pharmaceutical has disclosed Work In Process across 12 years of filings, most recently posting $412.4 million for Q3 2021.

• Quarterly Work In Process rose 39.01% year-over-year to $412.4 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $412.4 million (up 39.01% YoY) and the FY2020 annual result came in at $308.3 million, down 11.91% from the prior year.
• Work In Process climbed to $412.4 million in Q3 2021, from $374.0 million in the prior quarter.
• Over five years, Work In Process peaked at $412.4 million in Q3 2021 and troughed at $194.6 million in Q1 2018.
• A 5-year average of $295.3 million and a median of $296.7 million in 2020 frame the typical range for Work In Process.
• Annual changes were most pronounced in 2019 — Work In Process surged 51.46% — and 2020, when it slipped 11.91%.
• Tracing BMRN's Work In Process over 5 years: stood at $234.7 million in 2017, then slipped by 1.54% to $231.1 million in 2018, then jumped by 51.46% to $350.0 million in 2019, then dropped by 11.91% to $308.3 million in 2020, then soared by 33.78% to $412.4 million in 2021.
• Business Quant data shows BMRN's Work In Process at $412.4 million in Q3 2021, $374.0 million in Q2 2021, and $355.8 million in Q1 2021.